KMT2C is altered in 3.28% of medulloblastoma patients with KMT2C Mutation present in 3.12% of all medulloblastoma patients [4].

KMT2C Mutation is an inclusion criterion in 6 clinical trials for medulloblastoma, of which 6 are open and 0 are closed. Of the trials that contain KMT2C Mutation and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 4 (1 open) [5].

KMT2C Mutation is an inclusion criterion in 4 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 4 are open and 0 are closed. Of the trials that contain KMT2C Mutation and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [5].

KMT2C is altered in 2.44% of central nervous system embryonal neoplasm patients with KMT2C Mutation present in 2.22% of all central nervous system embryonal neoplasm patients [4].

KMT2C Mutation is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain KMT2C Mutation and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

KMT2C Mutation is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain KMT2C Mutation and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

KMT2C Mutation is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain KMT2C Mutation and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

KMT2C Mutation is an inclusion criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain KMT2C Mutation and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [5].

KMT2C Mutation is an inclusion criterion in 2 clinical trials for large cell/anaplastic medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain KMT2C Mutation and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [5].

KMT2C Mutation is an inclusion criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain KMT2C Mutation and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [5].

KMT2C Mutation is an inclusion criterion in 2 clinical trials for medulloblastoma, SHH-activated, of which 2 are open and 0 are closed. Of the trials that contain KMT2C Mutation and medulloblastoma, SHH-activated as inclusion criteria, 2 are phase 1 (2 open) [5].

KMT2C Mutation is an inclusion criterion in 2 clinical trials for medulloblastoma, WNT-activated, of which 2 are open and 0 are closed. Of the trials that contain KMT2C Mutation and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

KMT2C Mutation is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain KMT2C Mutation and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

KMT2C is altered in 11.08% of bladder carcinoma patients with KMT2C Mutation present in 12.26% of all bladder carcinoma patients [4].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2C Mutation and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

KMT2C is altered in 10.42% of anaplastic oligodendroglioma patients with KMT2C Mutation present in 10.59% of all anaplastic oligodendroglioma patients [4].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains KMT2C Mutation and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [5].

KMT2C is altered in 8.7% of anaplastic ependymoma patients with KMT2C Mutation present in 10.53% of all anaplastic ependymoma patients [4].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2C Mutation and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

KMT2C is altered in 9.83% of endometrial endometrioid adenocarcinoma patients with KMT2C Mutation present in 9.93% of all endometrial endometrioid adenocarcinoma patients [4].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2C Mutation and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

KMT2C is altered in 7.83% of malignant ovarian endometrioid tumor patients with KMT2C Mutation present in 9.92% of all malignant ovarian endometrioid tumor patients [4].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains KMT2C Mutation and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

KMT2C is altered in 7.46% of malignant ovarian clear cell tumor patients with KMT2C Mutation present in 8.47% of all malignant ovarian clear cell tumor patients [4].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for malignant ovarian clear cell tumor, of which 0 are open and 1 is closed. Of the trial that contains KMT2C Mutation and malignant ovarian clear cell tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

KMT2C is altered in 8.64% of breast carcinoma patients with KMT2C Mutation present in 6.48% of all breast carcinoma patients [4].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2C Mutation and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

KMT2C is altered in 7.08% of sarcomatoid carcinoma patients with KMT2C Mutation present in 6.48% of all sarcomatoid carcinoma patients [4].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for sarcomatoid carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2C Mutation and sarcomatoid carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

KMT2C is altered in 4.44% of ependymoma patients with KMT2C Mutation present in 6.45% of all ependymoma patients [4].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2C Mutation and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

KMT2C is altered in 6.2% of malignant solid tumor patients with KMT2C Mutation present in 5.69% of all malignant solid tumor patients [4].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains KMT2C Mutation and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

KMT2C is altered in 3.86% of glioblastoma patients with KMT2C Mutation present in 4.79% of all glioblastoma patients [4].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2C Mutation and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

KMT2C is altered in 4.1% of malignant glioma patients with KMT2C Mutation present in 4.78% of all malignant glioma patients [4].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains KMT2C Mutation and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

KMT2C is altered in 3.51% of diffuse glioma patients with KMT2C Mutation present in 4.21% of all diffuse glioma patients [4].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains KMT2C Mutation and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

KMT2C is altered in 6.02% of high-grade glioma, NOS patients with KMT2C Mutation present in 4.05% of all high-grade glioma, NOS patients [4].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains KMT2C Mutation and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [5].

KMT2C is altered in 3.06% of synovial sarcoma patients with KMT2C Mutation present in 3.53% of all synovial sarcoma patients [4].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for synovial sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2C Mutation and synovial sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

KMT2C is altered in 2.25% of anaplastic astrocytoma patients with KMT2C Mutation present in 2.53% of all anaplastic astrocytoma patients [4].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2C Mutation and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

KMT2C is altered in 2.12% of soft tissue sarcoma patients with KMT2C Mutation present in 1.96% of all soft tissue sarcoma patients [4].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2C Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains KMT2C Mutation and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains KMT2C Mutation and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [5].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2C Mutation and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains KMT2C Mutation and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains KMT2C Mutation and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains KMT2C Mutation and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [5].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains KMT2C Mutation and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [5].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains KMT2C Mutation and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [5].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for epithelioid sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2C Mutation and epithelioid sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2C Mutation and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [5].

KMT2C Mutation is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 0 are open and 1 is closed. Of the trial that contains KMT2C Mutation and rhabdoid tumor as inclusion criteria, 1 is phase 1 (0 open) [5].